Cel
The AIDA project aims to answer the question of clinical effectiveness and optimal dosing of 5 off-patent antibiotics for infections caused by multiple drug resistant (MDR) bacteria in three randomized controlled clinical trials. In an era of increasing emergence of drug resistance (EDR) and lack of new antibiotics, old off- patent antibiotics are increasingly being prescribed to patients. However, many of these were developed in an age before the advent of a structured process for drug assessment and approval, and the establishment of clinical efficacy and effectiveness in randomized controlled trials in particular. In a multidisciplinary approach the exposure response relationships for each antibiotic will be elucidated by including pharmacokinetic (PK), pharmacodynamic (PD) and microbiological studies, including emergence of drug resistance (EDR). The project addresses the optimization of treatment of infections caused by MDR pathogens that impose a major burden of disease in Europe and the rest of the world by selecting 5 off-patent-antibiotics that are increasingly being used without clear evidence with respect to their effectiveness, duration of therapy and issues of EDR. In the first trial the efficacy of colistin alone is compared to colistin plus imipenem for severe infections caused by carbapenem-resistant bacteria. The second trial compares fosfomycin vs. nitrofurantoin for the treatment of lower urinary tract infection in women at high risk of antibiotic-resistant pathogens. In the third trial antimicrobial oral treatment with minocycline plus rifampicin is compared with oral treatment with linezolid for complicated skin and soft tissue infections (cSSTI) due to MRSA. Exposure – response relationships, PK/PD and EDR issues will be addressed in a separate project component and is an essential element of the research project that will interrelate synergistically with the clinical studies. The results thereof will be used to refine exposure response relationships but also to study effects of exposure that are not readily observed in the trials. This will aid to delineate optimal exposures and drug dosing. This project addresses an urgent medical need that is critical both for individual patients and for society. An effective dissemination strategy is essential to effectively communicate project results to the target groups therefore supporting the project goal of preserving and strengthening the public health benefits of the studied off-patent antibiotics. The dissemination of project results to professional groups and the public in general, communication to policymakers, and implementation of results in national formularies is an important aspect.
Dziedzina nauki
- medical and health scienceshealth sciencespublic health
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesclinical medicineurology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
Zaproszenie do składania wniosków
FP7-HEALTH-2011-two-stage
Zobacz inne projekty w ramach tego zaproszenia
System finansowania
CP-FP - Small or medium-scale focused research projectKoordynator
3015 GD Rotterdam
Niderlandy
Zobacz na mapie
Uczestnicy (18)
69978 Tel Aviv
Zobacz na mapie
64239 Tel Aviv
Zobacz na mapie
751 05 Uppsala
Zobacz na mapie
2300 Kobenhavn S
Zobacz na mapie
1211 Geneve
Zobacz na mapie
10561 Athina
Zobacz na mapie
BS10 5NB Bristol
Zobacz na mapie
1180 Vienna
Zobacz na mapie
PE16 6AE CHATTERIS
Zobacz na mapie
86034 Poitiers Cedex
Zobacz na mapie
90419 Lodz
Zobacz na mapie
Zakończenie uczestnictwa
20123 Milano
Zobacz na mapie
Zakończenie uczestnictwa
M13 9PL Manchester
Zobacz na mapie
L69 7ZX Liverpool
Zobacz na mapie
31096 Haifa
Zobacz na mapie
81100 Caserta
Zobacz na mapie
6525 XZ Nijmegen
Zobacz na mapie
Zakończenie uczestnictwa
11000 Belgrade
Zobacz na mapie